TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, today announced that first clinical and new preclinical data on its lead investigational thrombolytic fusion protein, TGD001, have been selected for oral presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference is being held in Orlando, Florida, from December 6 to 9, 2025.
“Being granted two oral presentations by ASH underscores the scientific rigor of our work and the transformative potential of TGD001,” said Kristof Vercruysse, Chief Executive Officer of TargED Biopharmaceuticals. “The presented data highlight TGD001’s differentiated mechanism of action and reinforce its potential as a first-in-class, targeted therapy to redefine the standard of care across a broad spectrum of thrombotic diseases.”
For the first time, TargED Biopharmaceuticals will present Phase 1 clinical data from its first-in-human, randomized, double-blind, placebo-controlled single-ascending dose study, evaluating the safety, tolerability, and pharmacokinetics (PK) of intravenously administered TGD001 in 34 healthy adult male participants across four dose cohorts.
Additionally, the company will share preclinical findings demonstrating the efficacy of TGD001 across multiple in vivo models of thrombosis, including acute ischemic stroke (AIS), pulmonary embolism, and thrombotic thrombocytopenic purpura (TTP), underscoring its potential as a universal thrombolytic.
ASH 2025 Oral Presentations:
Novel von Willebrand Factor Targeting Thrombolytic TGD001 is Safe and Well Tolerated in a Phase 1 First-in-Human Trial
#5938
Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Old Dogs, New Tricks; Advances in Thrombotic Microangiopathy Diagnosis and Treatment
Monday, December 8, 2:45 PM – 4:15 PM ET Presentation Time: 3:15 PM ET
Novel von Willebrand Factor Targeting Thrombolytic TGD001 is Effective in Diverse Thrombotic Models, Demonstrating Its
#8142
Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Thrombosis and thrombotic microangiopathy: New mechanisms and new therapies
Saturday, December 6, 2:00 PM – 3:30 PM ET Presentation Time: 3:00 PM ET
Potential as a Universal Thrombolytic
Please refer to the ASH 2025 meeting program for full session details.